Definium Therapeutics has cleared a pivotal-level bar with the Voyage study, a Phase 3 RCT demonstrating statistically significant placebo-adjusted reduction in anxiety symptoms for DT120 (lysergide tartrate) in generalized anxiety disorder — a result that, combined with a prior late-stage win in major depressive disorder, establishes Phase 3 RCT evidence across two psychiatric indications. That is the ceiling of what this announcement substantiates. No quantitative efficacy figures — effect size, response rate, remission rate, or time to onset — appear in the press release, making independent evaluation of clinical meaningfulness impossible at this stage. The safety characterization ('favorable safety profile, consistent with prior studies') carries no adverse event rates, discontinuation figures, or description of specific psychoactive signals, which is the single sharpest evidentiary gap given the compound's mechanism. [1] DT120 is a serotonin 5-HT2A receptor agonist administered as a single oral dose — a combination of target, indication, and dosing paradigm for which no closely comparable regulatory or HTA precedent exists in the retrieved evidence. Esketamine nasal spray, the most structurally analogous approved psychoactive psychiatric agent, differs fundamentally: it is an NMDA receptor antagonist, it targets treatment-resistant depression rather than GAD, and it requires repeated supervised administration with a post-dose monitoring protocol — none of which maps to DT120's single-dose oral model. The esketamine precedent is therefore carried here only as a partial regulatory-feasibility signal — it demonstrates FDA and some HTA willingness to approve novel psychoactive mechanisms in psychiatry — not as a validated efficacy or access analogue. Where esketamine is instructive is in the scrutiny it attracted: the July 2022 PBAC review flagged uncertainty over comparator choice when switching to a new oral antidepressant was the primary comparator, and the July 2021 PBAC document documented treatment-emergent adverse events at 82.2% versus 45.5% placebo in the SUSTAIN-1 maintenance phase. DT120's placebo-only trial design in GAD — an indication with multiple approved generics including SSRIs, SNRIs, buspirone, benzodiazepines, and pregabalin — is likely to attract parallel HTA scrutiny absent active comparator data or a compelling justification for the comparator choice. On regulatory pathway, lysergide's Schedule I history introduces a DEA scheduling determination requirement before commercialization that has no parallel in the esketamine path. A REMS or restricted distribution program is plausible given the psychoactive mechanism. The sharpest unresolved risk is the single-dose durability question: GAD is a chronic condition, and the press release provides no follow-up duration, no re-dosing interval, and no maintenance strategy — gaps that will materially shape both FDA label negotiations and any cost-effectiveness model a payer or HTA body attempts to construct.
The Voyage study is a Phase 3 RCT meeting primary and key secondary endpoints — highest evidence tier — but no effect sizes, safety rates, or follow-up duration are disclosed, preventing assessment of clinical meaningfulness, durability, or payer-relevant cost-effectiveness. [2]
| Indication | Generalized anxiety disorder |
| Drug | Lysergide tartrate |
| Company | Definium Therapeutics |
| Trial Phase | Phase 3 |
| Trial Acronym | Voyage |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Neuroscience |
| Patient Population Size | 214 adults |
| Trial Duration | 12 weeks |
| Primary Endpoint Result | 5.4 points placebo-adjusted reduction from baseline |
| P-value | < 0.0001 |
| Analyst Expectation (Efficacy) | 5-point drop |
| Safety Profile | Favorable, No serious adverse events, No suicidality signal |
| Regulatory Designation | Breakthrough Therapy designation |
| Estimated Peak Sales (GAD) | $1.5 billion |
| NDA Filing Timeline | First half of next year |
| Second Phase 3 Study | Panorama |
Definium's Lysergide Tartrate Achieves Strong Phase 3 GAD Efficacy
Definium Therapeutics announced positive Phase 3 results for its single-dose oral lysergide tartrate (DT120) in generalized anxiety disorder (GAD). The Voyage study met its primary and key secondary efficacy endpoints, demonstrating a statistically significant placebo-adjusted reduction in anxiety symptoms. The drug exhibited rapid efficacy and a favorable safety profile, consistent with prior studies. This success marks a significant milestone for Definium's lead asset, following a previous late-stage win in major depressive disorder, and positions the company for a New Drug Application filing.
- Profound Efficacy and Rapid, Durable Effect: The Phase 3 Voyage study of lysergide tartrate (DT120) in 214 adults with GAD achieved a statistically significant placebo-adjusted reduction of 5.4 points from baseline (p < 0.0001) over 12 weeks. This magnitude of effect, observed as early as the second day, is noted by analysts as one of the strongest in GAD pivotal studies, offering a rapid and durable benefit significantly larger than currently approved treatments.
- Favorable Safety Profile and High Unmet Need: Lysergide tartrate (DT120) demonstrated a favorable safety profile, consistent with previous trials, with no serious adverse events or suicidality signals reported, and most patients ready for discharge within six hours. This safety, combined with the drug's efficacy, addresses a critical unmet need in GAD, a disorder with high prevalence and burden that has lacked innovation for decades, providing a promising single-dose option.
- Strong Regulatory Pathway and Market Potential: With FDA Breakthrough Therapy designation already secured for GAD, these positive Phase 3 results, alongside a prior MDD success, pave the way for Definium to file a New Drug Application in the first half of next year. Analysts project peak sales for DT120 in GAD to reach at least $1.5 billion, with potential for upward revision pending results from the upcoming Panorama study, highlighting substantial commercial prospects.
DT120's Landmark Phase 3 Results in GAD
Recent clinical investigations into GAD have evaluated both pharmacological efficacy and safety across a range of interventional approaches. The following studies represent notable contributions to the evidence base, spanning biomarker-guided treatment selection, meta-analytic synthesis, and large-scale pooled safety profiling.
LDAEP as a Predictor of Escitalopram Response (Escitalopram): In a 25-patient GAD cohort, pretreatment loudness dependence of the auditory evoked potential (LDAEP) was assessed as a predictive biomarker for treatment response. Pretreatment LDAEP positively correlated with CGI-S response rates at 4 and 8 weeks, and with HAM-A and BAI response rates at 8 weeks. Patients with a strong pretreatment LDAEP demonstrated higher HAM-A and CGI response rates at 8 weeks compared to those with a weak LDAEP. No safety outcomes were reported.
Agomelatine Meta-Analysis (Agomelatine): A meta-analysis of four double-blinded, randomized, placebo-controlled trials found that agomelatine significantly improved HAM-A total scores versus placebo (SMD = −0.56; p = 0.004). Odds ratios for response (≥50% HAM-A reduction) and remission (HAM-A ≤7) were 3.75 (p < 0.00001) and 2.74 (p < 0.00001), respectively. On the safety side, agomelatine was generally well tolerated, with no significant differences from placebo in dropout rates, somnolence, headache, nasopharyngitis, or dizziness; however, significantly higher incidences of liver function elevation (OR = 3.13; p = 0.01) and nausea (OR = 3.27; p = 0.02) were observed.
Duloxetine Pooled Safety Analysis (Duloxetine): A pooled analysis of 23,983 patients across 64 studies — including indications for MDD, GAD, DPNP, fibromyalgia, and LUTDs — characterized the broad safety profile of duloxetine. The most common treatment-emergent adverse events (TEAEs) included nausea, headache, dry mouth, insomnia, constipation, dizziness, fatigue, somnolence, diarrhea, and hyperhidrosis; the majority emerged early and were mild to moderate in severity. Overall discontinuation due to AEs occurred in 20.0% of patients, with SAEs reported in 3.5%. Cardiovascular and hepatic signals were modest: mean pulse increased by <2 bpm, systolic and diastolic blood pressure by <1 mmHg, and ALT/AST elevations by <2 U/L.
Dissecting the Voyage Study Design and Favorable Safety
The pivotal trials investigating treatments for Generalized Anxiety Disorder (GAD) span a diverse range of interventions and methodological frameworks, reflecting the heterogeneity of the therapeutic landscape. Across pharmacological, behavioral, and integrative modalities, study designs consistently anchored primary efficacy assessments to validated anxiety rating instruments, most notably the Hamilton Anxiety Scale (HAM-A/HAMA).
| Trial | Design | Population | Duration | Primary Endpoint | Key Secondary Endpoints |
|---|---|---|---|---|---|
| CBT vs. Enhanced Usual Care | Randomized controlled trial; CBT (n=70) vs. enhanced usual care (n=64) | 134 older adults (mean age 66.9 years); 2 primary care settings | 3 months treatment; follow-up at 6, 9, 12, 15 months | Penn State Worry Questionnaire; GAD Severity Scale | Hamilton Anxiety Rating Scale, Beck Anxiety Inventory, Beck Depression Inventory-II, SF-12 (physical/mental health QoL) |
| Duloxetine (Flexible-Dose) | 10-week, double-blind, progressive-titration, flexible-dose; duloxetine 60–120 mg (n=168) vs. placebo (n=159) | 327 adult outpatients | 10 weeks | Mean change from baseline in HAMA total score | HAMA response rate (≥50% reduction), CGI-I, Sheehan Disability Scale, VAS for pain, HADS, PGI-I |
| Duloxetine (Dual Placebo-Controlled Studies) | Two separate 9- to 10-week double-blind, placebo-controlled trials (Study 1: July 2004–Sep 2005; Study 2: Aug 2004–Jun 2005) | 840 patients randomized across both studies | 9–10 weeks | Mean change from baseline in HAMA total score | CGI-I, Sheehan Disability Scale, HADS, PGI-I |
| Flotation-REST | Randomized, parallel-group, non-blinded; 1:1 allocation; flotation-REST (n=24) vs. waitlist control (n=22) | 46 participants aged 18–65 years with GAD (self-report confirmation) | 12 sessions; 6-month follow-up | GAD symptomatology | Depression, sleep difficulties, emotion regulation difficulties, mindfulness |
| Sudarshan Kriya Yoga (SKY) | Open-label trial; single-arm | 41 enrolled / 31 completers; adults 18–65 years; primary GAD diagnosis (MINI); CGI-S 5–7; HAM-A ≥20; minimum 8 weeks prior standard anxiolytic treatment | 5-day SKY course (22 hours total); assessment at 4 weeks post-intervention | Mean change from baseline in HAM-A | None specified |
| Individualized Homeopathy | Double-blind, randomized, placebo-controlled, parallel-arm pilot; homeopathic medicine + counseling (n=31) vs. placebo + counseling (n=31) | 62 GAD patients; mean age 31.5 years; 56.5% male; recruitment rate 56%; retention rate 90% | 3 months | GAD-7 questionnaire | Hamilton Anxiety Scale (HAM-A) |
| Antianxiety Granule | Multicentre, randomized, double-blind, placebo-controlled, parallel-group; ITT analysis; 1–7 day screening, 6-week treatment, 1-week follow-up | Not individually specified | 6 weeks treatment + 1-week follow-up | Hamilton Anxiety Scale (HAMA) score | State-Trait Anxiety Inventory (STAI), TCM symptom scale |
Expanding Horizons: DT120's Pipeline Beyond GAD
Lysergide tartrate (LSD) is under active clinical investigation across a notably diverse range of psychiatric and pain-related indications beyond generalized anxiety disorder. The intervention models employed span from open-label exploratory studies to rigorously controlled randomized trials, reflecting the maturing clinical development landscape for this compound.
Major Depressive Disorder (MDD): Two dedicated trials are underway. LSDDEP1 is an open-label Phase 2A trial evaluating an 8-week microdosing regimen (6–20 μg twice weekly) in 19 participants. LSDDEP2 employs a more rigorous randomised, double-dummy, triple-blind, active placebo-controlled, parallel groups design, investigating the MB-22001 formulation (4–20 μg twice weekly for 8 weeks) in patients with MDD.
Alcohol Use Disorder: A meta-analysis of mid-20th century randomized controlled trials demonstrated that single-dose LSD regimens significantly improved outcomes in alcohol use disorder (OR 1.96; P < 0.0003), providing foundational evidence for this indication.
Anxiety and Depression in Life-Threatening Illness: Clinical trials in patients with anxiety and depression associated with life-threatening illnesses have shown that approximately 77% of participants demonstrate durable symptomatic relief at one year post-treatment.
Chronic Pain Conditions: Randomized controlled trials are being conducted in cluster headache, with additional investigational interest extending to phantom limb pain, fibromyalgia, and cancer- and palliative-related pain conditions.
Intervention Models Across Indications: The trial landscape encompasses open-label single-arm studies, randomised placebo-controlled parallel group designs, double-blind crossover studies, and double-dummy active placebo-controlled trials — reflecting a progression toward more robust, blinding-controlled methodologies.
Frequently Asked Questions
References
- [1] Baldwin DS, Ajel KI et al.. Pharmacological treatment of generalized anxiety disorder. Current topics in behavioral neurosciences. 2010. 21309121
- [2] Donegan CJ, Daldegan-Bueno D et al.. An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1). Pilot and feasibility studies. 2023 Oct 5. 37798662
- [3] Hartford JT, Endicott J et al.. Implications of pain in generalized anxiety disorder: efficacy of duloxetine. Primary care companion to the Journal of clinical psychiatry. 2008. 18615176
- [4] Daldegan-Bueno D, Donegan CJ et al.. LSD microdosing in major depressive disorder: results from an open-label trial. Neuropharmacology. 2026 Feb 1. 41202873
- [5] Robinson CL, Fonseca ACG et al.. Scoping Review: The Role of Psychedelics in the Management of Chronic Pain. Journal of pain research. 2024. 38496341
- [6] Ezeaka UC, Kim HJJ et al.. Addressing the Current Knowledge and Gaps in Research Surrounding Lysergic Acid Diethylamide (LSD), Psilocybin, and Psilocin in Rodent Models. Current topics in medicinal chemistry. 2023. 37409550
- [7] Verkuil B, Brosschot JF et al.. Capturing worry in daily life: are trait questionnaires sufficient?. Behaviour research and therapy. 2007 Aug. 17382896
- [8] Rynn M, Russell J et al.. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depression and anxiety. 2008. 17311303
- [9] Wang SM, Woo YS et al.. Agomelatine for the Treatment of Generalized Anxiety Disorder: A Meta-Analysis. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. 2020 Aug 31. 32702221
- [10] Parewa M, Burman AS et al.. Individualized Homeopathic Medicines in the Treatment of Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled, Pilot Trial. Complementary medicine research. 2021. 33662951
- [11] van der Meer PB, Fuentes JJ et al.. Therapeutic effect of psilocybin in addiction: A systematic review. Frontiers in psychiatry. 2023. 36846225
- [12] Prakash N, Pokowitz EL et al.. Mood Lifters for graduate students: Preventing the escalation of anxiety. Journal of American college health : J of ACH. 2025 Nov. 39566057
- [13] Kooijman NI, Willegers T et al.. Are psychedelics the answer to chronic pain: A review of current literature. Pain practice : the official journal of World Institute of Pain. 2023 Apr. 36597700
- [14] Mrakotsky C, Masek B et al.. Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia. Journal of anxiety disorders. 2008. 17419001
- [15] Jonsson K, Kjellgren A. Promising effects of treatment with flotation-REST (restricted environmental stimulation technique) as an intervention for generalized anxiety disorder (GAD): a randomized controlled pilot trial. BMC complementary and alternative medicine. 2016 Mar 25. 27016217
- [16] Maguire M, Ben-Menachem E et al.. A post-approval observational study to evaluate the safety and tolerability of perampanel as an add-on therapy in adolescent, adult, and elderly patients with epilepsy. Epilepsy & behavior : E&B. 2022 Jan. 34953337
- [17] Sha Z, Hou Y et al.. The efficacy and safety of 'antianxiety granule' for anxiety disorder: a multicentre, randomized, double-blind, placebo-controlled, parallel-group trial. Trials. 2020 Jan 23. 31973702
- [18] Gahimer J, Wernicke J et al.. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Current medical research and opinion. 2007 Jan. 17257478
- [19] Holze F, Caluori TV et al.. Safety pharmacology of acute LSD administration in healthy subjects. Psychopharmacology. 2022 Jun. 34515824
- [20] Katzman MA, Vermani M et al.. A multicomponent yoga-based, breath intervention program as an adjunctive treatment in patients suffering from generalized anxiety disorder with or without comorbidities. International journal of yoga. 2012 Jan. 22346068
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
